George Yancopoulos
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About George Yancopoulos
The proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $6,796,783 for George Yancopoulos in fiscal 2024, including a base salary of $1,941,100. Disclosed compensation is on record for 8 fiscal years. George Yancopoulos has spoken on 6 earnings calls across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on January 30, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Regeneron Pharmaceuticals, Inc. (REGN)
Source not stated
Current
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Regeneron Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- George D. Yancopoulos, M.D., Ph.D. Chairman
- Leonard S. Schleifer, M.D., Ph.D. Chairman
- Joseph J. LaRosa General Counsel
- Christine A. Poon Board Member
- Craig B. Thompson, M.D. Board Member
- David P. Schenkein Board Member
- David P. Schenkein, M.D. Board Member
- Huda Y. Zoghbi, M.D. Board Member
- Joseph L. Goldstein, M.D. Board Member
- Kathryn Guarini Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,941,100 | $6,796,783 |
| 2023 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,875,415 | $7,759,830 |
| 2022 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,811,995 | $6,593,696 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer Robert E. Landry (retired) | $1,767,800 | $6,398,364 |
| 2020 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,258,096 | $134,383,319 |
| 2019 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,170,500 | $20,664,135 |
| 2018 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer Robert E. Landry Executive Vice President, Finance and Chief Financial Officer | $1,130,900 | $25,381,129 |
| 2017 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,092,700 | $25,299,239 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.